Hero Image

Immunotherapy Treatments - Who Benefits and When to Start

Immunotherapy treatments are transforming cancer care, offering durable control and, for some, long-term remission.

If you’re newly diagnosed or weighing your next step after standard therapy, this guide explains who benefits, when to consider starting, what side effects to expect, and five breakthroughs changing the game—plus practical steps to get started.

Who Are Immunotherapy Treatments For?

Many solid tumors and blood cancers respond to modern immunotherapies, especially immune checkpoint inhibitors that target PD-1, PD-L1, or CTLA-4. Well-established uses include melanoma, non–small cell lung cancer, kidney (renal cell) cancer, bladder cancer, head and neck cancers, Hodgkin lymphoma, and certain colorectal and other tumors with mismatch repair deficiency (dMMR) or microsatellite instability–high (MSI-H). Learn the basics of immunotherapy from the National Cancer Institute. In some settings, these drugs are used after surgery (adjuvant) or before surgery (neoadjuvant) to reduce recurrence risk.

Biomarkers can guide fit and expected benefit. Common markers include PD-L1 expression, MSI-H/dMMR status, and tumor mutational burden (TMB). Higher PD-L1 or the presence of MSI-H/dMMR often predicts stronger responses. The FDA has granted tumor-agnostic approvals for pembrolizumab in MSI-H/dMMR tumors and in TMB-high cancers—see the FDA announcements here and here. You can read more about PD-L1, MSI, and TMB on NCI resources. That said, some people benefit even when markers are low or absent—especially when immunotherapy is combined with chemotherapy or targeted agents.

Not everyone is an ideal candidate right now. Extra caution is needed for people with active, severe autoimmune disease requiring immunosuppression, prior organ transplants (risk of rejection), uncontrolled infections, or poor functional status. Pregnancy requires a specialized risk–benefit discussion. For safety guidance on immune-related side effects, see the ASCO resources on immune-related adverse events.

When Should You Explore Immunotherapy?

At diagnosis of advanced disease

If your cancer is stage IV or has spread, ask about immunotherapy as a first-line option. In lung cancer, melanoma, kidney, bladder, and others, checkpoint inhibitors—such as pembrolizumab, nivolumab, and atezolizumab—often appear in standard-of-care regimens, either alone or with chemotherapy.

Before or after surgery

For select cancers, immunotherapy given before surgery (neoadjuvant) can shrink tumors and make procedures easier; given after surgery (adjuvant), it can reduce recurrence risk. Your team may reference event-free or disease-free survival data to guide timing.

After standard treatments stop working

Many patients start immunotherapy after progression on chemotherapy, targeted therapy, or radiation. Even then, responses can be long-lasting for a subset of people, sometimes outlasting the treatment itself.

Any time you’re eligible for a clinical trial

Don’t wait for a “last resort.” Clinical trials may offer access to the latest immunotherapy treatments and combinations earlier in care. Explore open studies on ClinicalTrials.gov or the NCI clinical trials search, and ask major cancer centers about options that match your tumor type and biomarkers.

Key Benefits of Immunotherapy

  • Durable responses: Some patients experience disease control that lasts years, even after stopping therapy.
  • Survival improvement: In several cancers, immunotherapy increases overall survival versus older standards.
  • Tumor-agnostic options: Approvals for MSI-H/dMMR and TMB-high tumors base treatment on biology, not just location—see FDA notes on MSI-H/dMMR and TMB-high.
  • Organ-sparing potential: Responses can sometimes avoid or delay major surgery, radiation, or multi-agent chemotherapy.
  • Quality-of-life advantages: While not side-effect free, many patients tolerate immunotherapy better than traditional chemotherapy.

Common Side Effects (5 to Know)

Because these drugs activate your immune system, side effects are called immune-related adverse events (irAEs). They’re usually manageable if treated early—report new symptoms promptly. For a patient-friendly overview, visit Cancer.Net’s immunotherapy guide.

  • Fatigue: The most common effect. Track energy levels, pace activities, and discuss labs to rule out anemia or thyroid issues.
  • Skin rash or itching: Use fragrance-free moisturizers and sun protection; mild steroid creams or antihistamines may help.
  • Diarrhea/colitis: New or worsening bowel changes can signal colon inflammation—call your team right away; steroids may be needed.
  • Thyroid problems (hypo/hyperthyroidism): Can cause weight changes, fatigue, or anxiety; blood tests and hormone replacement often control symptoms.
  • Lung inflammation (pneumonitis): New cough or shortness of breath is urgent; seek care promptly to prevent complications.

Other possible irAEs include hepatitis, adrenal or pituitary inflammation, joint pain, and infusion reactions. Early recognition is key.

5 New Immunotherapy Treatments Revolutionizing Cancer Care

Tumor-Infiltrating Lymphocyte (TIL) therapy

In 2024, the FDA approved the first TIL therapy for melanoma, validating an approach that expands a patient’s own tumor-fighting T cells and reinfuses them to attack cancer. Read the announcement, “FDA approves first cell therapy for solid tumors.” Trials are exploring TILs across additional solid tumors.

Personalized mRNA neoantigen vaccines

Custom vaccines built from your tumor’s unique mutations can “teach” the immune system what to attack. Early studies—often combined with PD-1 inhibitors—have shown promising reductions in recurrence risk in melanoma, with trials expanding to lung and other cancers. See phase 2 data in the New England Journal of Medicine.

Next-generation checkpoints: LAG-3 and beyond

Pairing PD-1/PD-L1 inhibitors with LAG-3 blockade has improved outcomes in melanoma. The FDA approved the fixed-dose combination of nivolumab and relatlimab (Opdualag) in 2022; details here. Agents targeting TIGIT and other checkpoints are in advanced trials and may help overcome resistance to single-agent therapy.

Bispecific T-cell engagers (BiTEs) and antibodies

These therapies bring T cells into direct contact with cancer cells. Several are approved in blood cancers and are moving into earlier lines of therapy and new tumor types. Examples include BCMA-targeted teclistamab for multiple myeloma (FDA approval) and CD20-targeted mosunetuzumab for follicular lymphoma (FDA approval).

Off-the-shelf cell therapies (allogeneic CAR-T/CAR-NK)

Unlike personalized autologous CAR-T, allogeneic approaches use donor cells, enabling faster starts and potentially broader access. Early trials show activity with improving safety profiles. Learn more from the NCI overview of “off-the-shelf” CAR T cells; natural killer (NK) cell engagers are also gaining momentum in studies.

Availability varies by country and indication. Ask your oncologist about approvals, access programs, or clinical trials relevant to your tumor type and biomarkers.

How to Get Started: A Step-by-Step Plan

  • Confirm your diagnosis and stage: Obtain pathology reports and imaging summaries.
  • Request biomarker testing: PD-L1, MSI/dMMR, TMB, and others can open immunotherapy paths. See NCI’s primer on tumor DNA and biomarker testing.
  • Discuss fit and timing: Review autoimmune history, transplant status, infection risks, medications (including steroids), and goals.
  • Evaluate options: Consider monotherapy vs. combination, adjuvant/neoadjuvant vs. metastatic settings, and trial eligibility.
  • Plan side-effect monitoring: Set early lab checks, symptom diaries, and clear contact instructions for urgent issues.
  • Address logistics: Work through insurance authorization, financial assistance, travel support, and infusion scheduling. Organizations like CancerCare and the Patient Advocate Foundation may help.
  • Seek a second opinion: Especially for rare cancers or complex choices—find NCI-Designated Cancer Centers.

Frequently Asked Questions

How long does immunotherapy last?

Many protocols treat for up to two years if tolerated and effective, though duration varies by cancer type and response. Some people stop earlier due to side effects or sustained remission.

Can I get vaccines while on immunotherapy?

Inactivated vaccines (like the seasonal flu shot) are generally acceptable; live vaccines are typically avoided. Always confirm timing with your oncology team. See practical guidance on Cancer.Net.

Will I feel well enough to work or travel?

Many people continue normal activities with adjustments. Plan around infusion days, track fatigue, and carry emergency contact info when traveling. Ask your care team for personalized advice.

The Bottom Line

Immunotherapy treatments have reshaped cancer care—offering longer survival and, for some, lasting remission. With the right biomarkers, timing, and monitoring, you and your oncology team can decide if, when, and how to integrate these powerful therapies into your plan. Always discuss individual risks, benefits, and clinical trial opportunities to make an informed choice.